Lifecore Biomedical Inc. (LFCR) - Net Assets
Based on the latest financial reports, Lifecore Biomedical Inc. (LFCR) has net assets worth $20.78 Million USD as of February 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($225.50 Million) and total liabilities ($204.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore LFCR current and non-current assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $20.78 Million |
| % of Total Assets | 9.21% |
| Annual Growth Rate | N/A |
| 5-Year Change | -113.16% |
| 10-Year Change | -106.22% |
| Growth Volatility | 210.74 |
Lifecore Biomedical Inc. - Net Assets Trend (1996–2026)
This chart illustrates how Lifecore Biomedical Inc.'s net assets have evolved over time, based on quarterly financial data. Check LFCR goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Lifecore Biomedical Inc. (1996–2026)
The table below shows the annual net assets of Lifecore Biomedical Inc. from 1996 to 2026. For live valuation and market cap data, see Lifecore Biomedical Inc. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2026-05-31 | $-14.20 Million | -1163.02% |
| 2025-05-31 | $1.34 Million | -88.19% |
| 2024-05-31 | $11.31 Million | -87.12% |
| 2023-05-31 | $87.82 Million | -18.64% |
| 2022-05-31 | $107.94 Million | -46.77% |
| 2021-05-31 | $202.78 Million | -12.23% |
| 2020-05-31 | $231.04 Million | -14.47% |
| 2019-05-31 | $270.14 Million | +6.96% |
| 2018-05-31 | $252.56 Million | +10.70% |
| 2017-05-31 | $228.15 Million | +7.44% |
| 2016-05-31 | $212.35 Million | -3.53% |
| 2015-05-31 | $220.11 Million | +7.50% |
| 2014-05-31 | $204.76 Million | +13.50% |
| 2013-05-31 | $180.41 Million | +19.04% |
| 2012-05-31 | $151.56 Million | +10.04% |
| 2011-05-31 | $137.73 Million | +3.96% |
| 2010-05-31 | $132.47 Million | +4.15% |
| 2009-05-31 | $127.20 Million | +9.64% |
| 2008-05-31 | $116.02 Million | +3.52% |
| 2007-05-31 | $112.07 Million | +29.09% |
| 2006-05-31 | $86.82 Million | +18.08% |
| 2005-05-31 | $73.53 Million | +16.52% |
| 2004-05-31 | $63.10 Million | +5.87% |
| 2003-05-31 | $59.60 Million | +3.58% |
| 2002-05-31 | $57.54 Million | +13.11% |
| 2001-05-31 | $50.87 Million | -10.74% |
| 2000-05-31 | $57.00 Million | +79.24% |
| 1999-05-31 | $31.80 Million | -5.64% |
| 1998-05-31 | $33.70 Million | -5.34% |
| 1997-05-31 | $35.60 Million | -2.73% |
| 1996-05-31 | $36.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lifecore Biomedical Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19190100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (May 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.00K | % |
| Other Components | $208.96 Million | % |
| Total Equity | $-14.20 Million | 100.00% |
Lifecore Biomedical Inc. Competitors by Market Cap
The table below lists competitors of Lifecore Biomedical Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hirequest Inc
NASDAQ:HQI
|
$162.54 Million |
|
NX Filtration Holding BV
AS:NXFIL
|
$162.55 Million |
|
Smart Gunes Enerjisi Teknolojileri Arastirma Gelistirme Uretim Sanayi ve Ticaret
IS:SMRTG
|
$162.57 Million |
|
Central Hydropower JSC
VN:CHP
|
$162.63 Million |
|
Nkarta Inc
NASDAQ:NKTX
|
$162.41 Million |
|
Arbor Technology
TWO:3594
|
$162.27 Million |
|
Invesco Trust For Inv Grade NY Munis
NYSE:VTN
|
$162.23 Million |
|
So-Young International Inc
NASDAQ:SY
|
$162.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lifecore Biomedical Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 1,336,000 to -14,202,000, a change of -15,538,000 (-1163.0%).
- Other factors decreased equity by 15,538,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $0.00 | -0.0% |
| Other Changes | $-15.54 Million | -109.41% |
| Total Change | $- | -1163.02% |
Book Value vs Market Value Analysis
This analysis compares Lifecore Biomedical Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-05-31 | $4.68 | $4.33 | x |
| 1997-05-31 | $3.19 | $4.33 | x |
| 1998-05-31 | $2.53 | $4.33 | x |
| 1999-05-31 | $3.18 | $4.33 | x |
| 2000-05-31 | $3.54 | $4.33 | x |
| 2001-05-31 | $3.04 | $4.33 | x |
| 2002-05-31 | $3.08 | $4.33 | x |
| 2003-05-31 | $2.49 | $4.33 | x |
| 2004-05-31 | $2.61 | $4.33 | x |
| 2005-05-31 | $2.93 | $4.33 | x |
| 2006-05-31 | $3.31 | $4.33 | x |
| 2007-05-31 | $4.15 | $4.33 | x |
| 2008-05-31 | $4.25 | $4.33 | x |
| 2009-05-31 | $4.75 | $4.33 | x |
| 2010-05-31 | $4.91 | $4.33 | x |
| 2011-05-31 | $5.11 | $4.33 | x |
| 2012-05-31 | $5.73 | $4.33 | x |
| 2013-05-31 | $6.71 | $4.33 | x |
| 2014-05-31 | $7.49 | $4.33 | x |
| 2015-05-31 | $7.99 | $4.33 | x |
| 2016-05-31 | $7.76 | $4.33 | x |
| 2017-05-31 | $8.20 | $4.33 | x |
| 2018-05-31 | $9.05 | $4.33 | x |
| 2019-05-31 | $9.44 | $4.33 | x |
| 2020-05-31 | $7.92 | $4.33 | x |
| 2021-05-31 | $6.92 | $4.33 | x |
| 2022-05-31 | $3.66 | $4.33 | x |
| 2023-05-31 | $2.98 | $4.33 | x |
| 2024-05-31 | $0.31 | $4.33 | x |
| 2025-05-31 | $0.04 | $4.33 | x |
| 2026-05-31 | $-0.38 | $4.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lifecore Biomedical Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2897.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -30.04%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 179.15x
- Recent ROE (-2897.98%) is below the historical average (-104.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -11.48% | -168.00% | 0.07x | 1.05x | $-7.86 Million |
| 1997 | -24.16% | -90.53% | 0.19x | 1.41x | $-12.16 Million |
| 1998 | -8.61% | -8.66% | 0.79x | 1.26x | $-6.27 Million |
| 1999 | -8.81% | -7.91% | 0.87x | 1.28x | $-5.98 Million |
| 2000 | -7.16% | -1.91% | 1.69x | 2.22x | $-9.58 Million |
| 2001 | -37.70% | -9.84% | 1.59x | 2.41x | $-23.77 Million |
| 2002 | -2.66% | -0.81% | 1.70x | 1.93x | $-7.08 Million |
| 2004 | 4.71% | 1.51% | 2.07x | 1.51x | $-3.25 Million |
| 2005 | 7.50% | 2.63% | 2.05x | 1.39x | $-1.80 Million |
| 2006 | 10.17% | 3.73% | 1.95x | 1.40x | $146.10K |
| 2007 | 26.48% | 13.87% | 1.49x | 1.28x | $18.17 Million |
| 2008 | 11.83% | 5.68% | 1.58x | 1.32x | $2.10 Million |
| 2009 | 6.08% | 3.28% | 1.54x | 1.20x | $-4.99 Million |
| 2010 | 3.05% | 1.67% | 1.19x | 1.53x | $-9.09 Million |
| 2011 | 2.88% | 1.42% | 1.34x | 1.52x | $-9.69 Million |
| 2012 | 8.48% | 4.00% | 1.14x | 1.85x | $-2.28 Million |
| 2013 | 12.64% | 5.11% | 1.52x | 1.63x | $4.72 Million |
| 2014 | 9.43% | 4.02% | 1.52x | 1.54x | $-1.16 Million |
| 2015 | 6.20% | 2.51% | 1.56x | 1.59x | $-8.30 Million |
| 2016 | -5.52% | -2.15% | 1.58x | 1.63x | $-32.71 Million |
| 2017 | 4.67% | 1.99% | 1.49x | 1.58x | $-12.07 Million |
| 2018 | 9.83% | 4.74% | 1.30x | 1.60x | $-427.20K |
| 2019 | 0.79% | 0.38% | 1.07x | 1.92x | $-24.89 Million |
| 2020 | -16.53% | -23.86% | 0.30x | 2.34x | $-61.30 Million |
| 2021 | -15.93% | -32.01% | 0.20x | 2.48x | $-52.57 Million |
| 2022 | -90.26% | -52.44% | 0.63x | 2.73x | $-108.23 Million |
| 2023 | -132.90% | -104.89% | 0.41x | 3.13x | $-125.50 Million |
| 2024 | 106.17% | 9.37% | 0.51x | 22.44x | $10.88 Million |
| 2025 | -2897.98% | -30.04% | 0.54x | 179.15x | $-38.85 Million |
Industry Comparison
This section compares Lifecore Biomedical Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $620,309,962
- Average return on equity (ROE) among peers: -5.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lifecore Biomedical Inc. (LFCR) | $20.78 Million | -11.48% | 9.85x | $162.42 Million |
| Aurora Cannabis Inc (ACB) | $4.40 Billion | -6.66% | 0.28x | $157.87 Million |
| Akanda Corp (AKAN) | $-5.03 Million | 0.00% | 0.00x | $4.13 Million |
| Akebia Ther (AKBA) | $131.00 Million | -46.35% | 0.09x | $326.81 Million |
| Alkermes Plc (ALKS) | $419.23 Million | -9.45% | 0.24x | $7.49 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-151.17 Million | 0.00% | 0.00x | $1.64 Billion |
| Amphastar P (AMPH) | $445.52 Million | 13.94% | 0.51x | $825.42 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-175.94 Million | 0.00% | 0.00x | $5.21 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $26.20 Million | 12.60% | 0.10x | $196.52 Million |
| ANI Pharmaceuticals Inc (ANIP) | $212.79 Million | 2.86% | 1.15x | $1.74 Billion |
About Lifecore Biomedical Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device … Read more